Spesolimab now approved for pustular psoriasis in adolescents

Spesolimab-sbzo (Spevigo), an IL-36 receptor antagonist, is now indicated for the treatment of generalized pustular psoriasis in adults and pediatric patients ≥12 years of age and weighing ≥40 kg. Previously the drug was approved only for use in adults. Safety and efficacy were established in the phase 2 Effisayil-2 trial.